ELDN Eledon Pharmaceuticals, Inc.
NEUTRAL
Impact: 3/10
PRESS-RELEASE
Press release: fda
Latest settled — T+5d
ELDN ▼ -0.51% at T+5d
NEUTRAL call ✗ call lost -0.51% · α vs SPY -2.11% · entry $3.89 → $3.87
Currently $3.57 · -8.23% from $3.89 entry
T+1d
0.00%
call 0.00% · α -0.45%
$3.89
settled 23d ago
T+5d
-0.51%
call -0.51% · α -2.11%
$3.87
settled 16d ago
T+20d
—
call — · α —
—
in 5d
T+60d
—
call — · α —
—
in 2mo
Price Chart
Loading chart...
Executive Summary
Eledon Pharmaceuticals will present new clinical data from its tegoprubart Phase 2 BESTOW trial and extension study at the American Transplant Congress in June 2026. No actual results are disclosed in this announcement; the event is a routine pipeline update for a clinical-stage biotech.
Actionable Insight
Monitor the June 22 conference call for actual efficacy/safety data from the BESTOW trial. Stock may move on data quality, not on this announcement.
Key Facts
- Oral and poster presentations at ATC (June 20–24, 2026) covering tegoprubart in kidney transplantation
- Investor conference call scheduled for June 22, 2026 at 8:00 AM ET to discuss the data
Financial Impact
No financial impact disclosed; pure data disclosure event
Risk Factors
- Clinical trial data may disappoint, leading to negative stock reaction
- Competition from other anti-CD40L antibodies or standard-of-care immunosuppressants
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3298862 |
3 reports for ELDN
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 20, 2026
23d ago
|
Press Release
| $3.89 $3.87 | ▼ −0.51% | ▼ −2.11% | $3.57 (−8.23%) |
|
Mar 10, 2026
13w ago
|
Press Release
| $2.90 $2.88 | ▼ −0.69% | ▲ +0.22% | $3.57 (+23.10%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $2.66 $2.90 | ▲ +9.02% | ▲ +10.23% | $3.57 (+34.21%) |
Showing 3 of 3
US Market Status
Market Closed — Opens Mon (49h 41m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access